Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Tekmira Conference Call and Webcast Advisory: First Quarter 2011 Operating Results and Corporate Update

Abstract:
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will hold a conference call and webcast on Tuesday, May 10, 2011 at 1:30 pm Pacific Time (4:30 pm Eastern Time) to discuss its first quarter operating results and a summary of corporate highlights.

Tekmira Conference Call and Webcast Advisory: First Quarter 2011 Operating Results and Corporate Update

Vancouver, Canada | Posted on May 4th, 2011

Conference Call Information

To access the conference call, please dial 914-495-8556 or 1-866-393-1607. The live webcast can be accessed through the Investor section of Tekmira's website at www.tekmirapharm.com.

An archived webcast will be available on the Tekmira website approximately two hours after the event. In addition, a replay of the conference call will be available until May 17, 2011 by calling 706-645-9291 or 1-800-642-1687.

About RNAi and Tekmira's LNP Technology

RNAi therapeutics have the potential to treat a broad number of human diseases by "silencing" disease causing genes. The discoverers of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi therapeutics, such as "siRNAs," require delivery technology to be effective systemically. LNP technology is one of the most widely used siRNA delivery approaches for systemic administration. Tekmira's LNP technology (formerly referred to as stable nucleic acid-lipid particles or SNALP) encapsulates siRNAs with high efficiency in uniform lipid nanoparticles which are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models. Tekmira's LNP formulations are manufactured by a proprietary method which is robust, scalable and highly reproducible and LNP-based products have been reviewed by multiple FDA divisions for use in clinical trials. LNP formulations comprise several lipid components that can be adjusted to suit the specific application.

####

About Tekmira Pharmaceuticals Corporation
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

For more information, please click here

Contacts:
Investors
Jodi Regts
Director, Investor Relations
Phone: 604-419-3234
Email:

Media
David Ryan
Longview Communications Inc.
Phone: 416-669-7906
Email:

Copyright © GlobeNewswire, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Recruiting bacteria to be technology innovation partners: September 17th, 2014

Nanoscience makes your wine better September 17th, 2014

Nanoribbon film keeps glass ice-free: Rice University lab refines deicing film that allows radio frequencies to pass September 16th, 2014

Effective Nanotechnology Innovations to Receive Mustafa Prize September 16th, 2014

Nanomedicine

Recruiting bacteria to be technology innovation partners: September 17th, 2014

Nanoscience makes your wine better September 17th, 2014

Treatment of Cell Infection by Nanotechnology September 15th, 2014

Iranian Nanotechnology Scientists Produce Polymeric Scaffolds for Tissue Engineering September 11th, 2014

Announcements

Nanoscience makes your wine better September 17th, 2014

Carbon Sciences Developing Breakthrough Technology to Mass-Produce Graphene -- the New Miracle Material: Company Enters Into an Agreement With the University of California, Santa Barbara (UCSB) to Fund the Further Development of a New Graphene Process September 16th, 2014

Nanoribbon film keeps glass ice-free: Rice University lab refines deicing film that allows radio frequencies to pass September 16th, 2014

Effective Nanotechnology Innovations to Receive Mustafa Prize September 16th, 2014

Financial Reports

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520 August 12th, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 August 12th, 2014

Harris & Harris Group Reports Financial Statements as of June 30, 2014 August 10th, 2014

Events/Classes

Dolomite to launch Meros TCU-100 temperature controller at Lab-on-a-Chip & Microarray World Congress September 15th, 2014

Seeking Nanoscale Defenses for Biological and Chemical Threats: WPI co-organizes a NATO workshop to improve the detection and decontamination of biological and chemical agents September 13th, 2014

PETA science consortium experts to present at international nanotechology workshop: PETA International Science Consortium, Ltd., Is a Sponsor of Nano Risk Analysis II September 12th, 2014

DELMIC and Phenom-World announce Delphi, the world’s first fully integrated tabletop fluorescence and electron microscope September 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE